Subcutaneous Delivery Articles & Analysis
9 news found
SeValent is designed to enable intravenous (IV)-only therapies to now be delivered subcutaneously in a controlled manner for use in the home setting. "The allowance is significant as it protects our novel salt formulation technology across a broad platform of therapeutic areas,” commented Jeffrey Becker, MD, Chief Scientific Officer. “There has been little ...
Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions through new formulations designed for subcutaneous delivery. Bexson’s proprietary platform, SeValent™, can be applied to small molecules across a broad range of drug classes, enabling IV therapies to be ...
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today positive results from high-level data from its Phase 1 study of STAR-LLD, evaluating the pharmacokinetics (PK) and safety of the Company’s continuous delivery lenalidomide program. The Phase 1 study met all of its primary and secondary endpoints; in all subjects ...
Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing subcutaneous therapies for pain management and mental health disorders, announced today that they have signed an ...
Sun joins Mammoth from Halozyme Therapeutics Inc., a public biotechnology company focused on the subcutaneous delivery of biologics and small molecule therapeutics, where she served as Senior Vice President and CFO, leading the company’s finance, accounting, information technology, site operations and the Hylenex® commercial business. ...
Our expert discusses the growing trend of moving away from intravenous drugs administered in clinical and hospital settings to at-home, self-administered vial-based subcutaneous delivery for cost savings, better lifecycle management and improved care. Learn more about our technology by reading the latest article in On Drug ...
Bexson believes the new utilities identified in this patent will allow safety, comfort and pharmacokinetics that greatly improve ketamine administration for multiple routes of administration, including subcutaneous. Formulated for subcutaneous delivery, Bexson's ketamine-based pain therapy aims to be an alternative to opioids. ...
As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer, Stevanato Group. ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the ...